Hydroxychloroquine: Novartis reaches agreement with FDA to proceed with a Phase III clinical trial in hospitalized COVID-19 patients

Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The clinical trial drug supply will be provided by Sandoz, the generics and biosimilars division ["]

The post Hydroxychloroquine: Novartis reaches agreement with FDA to proceed with a Phase III clinical trial in hospitalized COVID-19 patients appeared first on Outbreak News Today.